NOD-like Receptor (NLR)

Related Products

Nucleotide oligomerization domain (NOD)-like receptors (NLRs) are critical cytoplasmic pattern-recognition receptors (PRRs) that play an important role in the host innate immune response and immunity homeostasis. There are 23 NLR family members in humans and at least 34 NLR genes in mice. NLRs are expressed in many cell types including immune cells and epithelial cells, although certain NLR family members are expressed primarily in phagocytes including macrophages and neutrophils. The NLR family are most commonly classified according to their N-terminal domain, falling into one of four subfamilies; NLRA, NLRB, NLRC and NLRP.

The NLRs recognize various ligands from microbial pathogens (peptidoglycan, flagellin, viral RNA, fungal hyphae, etc.), host cells (ATPs, cholesterol crystals, uric acid, etc.), and environmental sources (alum, asbestos, silica, alloy particles, UV radiation, skin irritants, etc.). Most NLRs act as PRRs, recognizing the above ligands and activate inflammatory responses. However, some NLRs may not act as PRRs but instead respond to cytokines such as interferons. The activated NLRs show various functions that can be divided into four broad categories: inflammasome formation, signaling transduction, transcription activation, and autophagy.

NOD-like Receptor (NLR) Related Products (138)
Antibodies (2)

By Effects:	Inhibitors (104) Agonists (6) Antagonists (5) Activators (14) Modulators (2)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-116084S

Trimethylamine N-oxide-d₉	Activator	≥99.0%
Trimethylamine N-oxide-d₉ is the deuterium labeled Trimethylamine N-oxide. Trimethylamine N-oxide is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide induces inflammation by activating the ROS/NLRP3 inflammasome. Trimethylamine N-oxide also accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis by activating the TGF-β/smad2 signaling pathway[1][2][3].

HY-151343

NLRP3-IN-10	Inhibitor	98.97%
NLRP3-IN-10 is a potent NLRP3 inhibitor, inhibits IL-1β release with an IC₅₀ value of 251.1 nM. NLRP3-IN-10 suppresses NLRP3 inflammasome activation by attenuating ASC speck formation.

HY-156438

NT-0796	Inhibitor	99.65%
NT-0796 is a selective and CNS-penetrant NLRP3 inflammasome inhibitor with an IC₅₀ of 0.32 nM in PBMC assay. NT-0796 is an isopropyl ester that undergoes intracellular conversion to NDT-19795, the carboxylic acid active species. NT-0796 has the potential for neuroinflammatory diseases research.

HY-13682B

Mifamurtide sodium		≥98.0%
Mifamurtide sodium (MTP-PE sodium), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide sodium is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide sodium has potential for use in rare disease and osteosarcoma research.

HY-156647

Usnoflast	Modulator	98.29%
Usnoflast is a NLRP3 modulator, as well as a non-steroidal anti-inflammatory agent (NSAD).

HY-156413

NLRP3 agonist 1	Agonist	99.01%
NLRP3 agonist 1 (compound 23) is a potent and orally active NLRP3 agonist. NLRP3 agonist 1 can activate the enzyme Caspase-1 to cleave pro-IL-1β and pro-IL-18 proinflammatory cytokines into their mature forms.

HY-151252

NIC-0102	Inhibitor	98.72%
NIC-0102 is an orally active proteasome inhibitor (pIC₅₀=7.55) that specifically inhibits NLRP3 inflammatory vesicle activation. NIC-0102 shows potent anti-inflammatory effects in a model of dextran sulfate sodium (DSS)-induced ulcerative colitis. NIC-0102 also inhibits production of pro-IL-1β.

HY-W011082

NLRP3-IN-2	Inhibitor	98.00%
NLRP3-IN-2, an intermediate substrate in the synthesis of glyburide, inhibits the formation of the NLRP3 inflammasome in cardiomyocytes and limits the infarct size following myocardial ischemia/reperfusion in the mouse, without affecting glucose metabolism.

HY-W082785A

L6H21	Inhibitor	99.46%
L6H21, a Chalcone (HY-121054) derivative, is an orally active, potent and specific myeloid differentiation 2 (MD-2) inhibitor. L6H21 directly binds to MD-2 protein with a high affinity and low K_D value of 33.3 μM, blocking the formation of the LPS-TLR4/MD-2 complex. L6H21 inhibits LPS-induced expression of TNF-α and IL-6 in RAW264.7 macrophages, with IC₅₀ values of 6.58 and 8.59 μM, respectively. L6H21 can be used for alcoholic liver disease, metabolic disturbance and neuroinflammation research.

HY-153554

NLRP3-IN-18	Inhibitor	98.06%
NLRP3-IN-18 (compound 13) is a potent NLRP3 inhibitor with an IC₅₀ value of ≤1.0 µM.

HY-130494

(±)11(12)-EET	Inhibitor	≥98.0%
(±)11(12)-EET is a NLRP3 inflammasome inhibitor. (±)11(12)-EET can be used for the research of anti-inflammatory, angiogenic and cardioprotective.

HY-117432

JC-171	Inhibitor	98.41%
JC-171 is a selective NLRP3 inflammasome inhibitor, with an IC₅₀ of 8.45 μM for inhibiting LPS/ATP-induced interleukin-1β (IL-1β) release from J774A.1 macrophages.

HY-137888A

Oxidized ATP trisodium salt	Inhibitor	≥98.0%
Oxidized ATP (oATP) trisodium salt is a broad-spectrum P2 receptor inhibitor. Oxidized ATP trisodium salt irreversibly antagonizes P2X7R activation. Oxidized ATP trisodium salt inhibits c-reactive protein (CRP)-induced NLRP3 inflammasome activation. Oxidized ATP trisodium salt can be used for research of atherosclerosis.

HY-148187

NLRP3-IN-11	Inhibitor	98.79%
NLRP3-IN-11 is a NLR family pyrin domain containing 3 (NLRP3) proteins inhibitor. NLRP3-IN-11 has biological activity for NLRP3 with an IC₅₀ value of <0.3 μM. NLRP3-IN-11 can be used for the researh of inflammatory and degenerative diseases including NASH, atherosclerosis and other cardiovascular diseases, Alzheimer's disease, Parkinson's disease, diabetes, gout, and numerous other autoinflammatory diseases.

HY-121988

INF4E	Inhibitor	99.38%
INF4E is a potent NLRP3 inflammasome inhibitor. INF4E inhibits caspase-1 and NLRP3 ATPase activities. INF4E shows protection against the IR-induced myocardial injury and dysfunction.

HY-155751

HMGB1-IN-1	Inhibitor
HMGB1-IN-1 (compound 6) displays strong NO inhibitory effect in RAW264.7 cells with IC₅₀ value of 15.9 ± 0.6 μM. HMGB1-IN-1 inhibit the HMGB1/NF-κB/NLRP3 pathway. HMGB1-IN-1 shows good anti-inflammatory activity and good anti-sepsis effects in kidney injury.

HY-153261

NLRP3-IN-17	Inhibitor	99.23%
NLRP3-IN-17 is a potent, selective and orally active NLRP3 inflammasome inhibitor with an IC₅₀ value of 7 nM. NLRP3-IN-17 significantly inhibits NLRP3 dependent IL-1β secretion in mice and can be used for chronic inflammatory diseases research.

HY-131040

NLRP3-IN-NBC6	Inhibitor	99.40%
NLRP3-IN-NBC6 is a potent, selective NLRP3 inflammasome inhibitor (IC₅₀= 574 nM) that acts independently of Ca²⁺. NLRP3-IN-NBC6 inhibits Nigericin (HY-127019)-induced inflammasome activation in THP-1 cells and Imiquimod (HY-B0180)-induced IL-1β release from LPS-primed bone marrow-derived macrophages (BMDMs).

HY-B0516

Articaine hydrochloride	Activator	98.46%
Articaine hydrochloride (Hoe-045) is an amide anaesthetic containing an ester group, reversibly binding to the α-subunit of the voltage-gated sodium channels within the inner cavity of the nerve, can provide effective pain relief. Articaine hydrochloride ameliorates LPS-induced acute kidney injury via inhibition of NF-ĸB activation and the NLRP3 inflammasome pathway.

HY-N0139R

Troxerutin (Standard)	Inhibitor
Troxerutin (Standard) is the analytical standard of Troxerutin. This product is intended for research and analytical applications. Troxerutin, also known as vitamin P4, is a tri-hydroxyethylated derivative of natural bioflavonoid rutins which can inhibit the production of reactive oxygen species (ROS) and depress ER stress-mediated NOD activation.

Name
Email *

	Sorry, but the email address you supplied was invalid.

NOD-like Receptor (NLR)

NOD-like Receptor (NLR)

NOD-like Receptor (NLR) Related Products (138)

Antibodies (2)

NOD-like Receptor (NLR) Related Products (138):